StocksDaily @IntradayRider

$BBNX prices $150M public offering — Pricing 7,652,175 shares of common stock at $17.25 per share, plus pre-funded warrants for 1,043,484 shares — Gross proceeds expected around $150 million before fees — Underwriters have a 30-day option for up to 1,304,348 additional shares — Expected to close on or about September 17 — Proceeds earmarked for Mint commercialization, manufacturing expansion, R&D, and working capital Not financial advice.

$HQ Horizon Quantum issues clarification after "incorrect information" circulated on the stock yesterday — Confirms share count: 34.81M Class A + 19.74M Class B outstanding as of Sept 14 — Confirms all business combination lock-ups still in effect, none have expired — Lock-ups run until March 19, 2028 (24mo post-close), except one holder at Sept 19, 2027 (18mo) — No share count inflation, no early lock-up expiry — company explicitly shutting down the rumor Direct rebuttal filing — worth checking what specific rumor/misinformation was circulating yesterday before this dropped Not financial advice.

$AGPU $MEDS Axe Compute sells legacy Helomics oncology diagnostics unit to DataMEDS AI for stock — Sold entirely for DataMEDS common shares/equivalents, no cash — Completes Axe Compute's full transition to pure-play neocloud GPU-as-a-Service — Helomics was the last remnant of its former identity as Predictive Oncology (renamed Dec 2025) — DataMEDS (formerly Wellgistics Health) gets its entry into oncology diagnostics — Full terms to come via 8-K filing Clean identity resolution for Axe Compute — shareholders keep upside via DataMEDS stake instead of a cash exit Not financial advice.

$CNTB Connect Biopharma reports Phase 2 Seabreeze STAT asthma topline for rademikibart — Day 7 FEV1: +250mL vs +120mL placebo, statistically significant (p=0.023) — Treatment failure rate cut ~66% at 28 days, but missed significance (p=0.153) due to lower-than-projected placebo failure rate — 50% fewer ED/unscheduled visits vs placebo — Safety clean: 1 SAE on drug vs 3 on placebo, comparable AE rates — COPD companion trial data due later this month, then FDA meeting targeted for Phase 3 alignment — Simcere holds Greater China rights, up to ~$99M in remaining milestones for Connect Real efficacy signal on lung function, but the headline efficacy number (66% reduction in treatment failure) didn't hit statistical significance — worth flagging clearly Not financial advice.

$MIMI Mint's Rice AI subsidiary licenses Pudgy Penguins IP for co-branded "Blue Pengu Minibot" — Non-exclusive worldwide license to Rice AI for a limited-edition AI companion robot with the Pengu character — Rice AI covers all production/marketing costs, owns compliance, warranty, after-sales — Sold via e-commerce and physical retail Rice AI controls — Limited initial drop, positioned as collectible + functional companion robot — Part of Mint's broader AI/robotics push alongside its legacy interior design/fit-out business Consumer culture crossover play — real IP deal, but scale/revenue impact unclear given "limited-edition" framing Not financial advice.

$VRA Vera Bradley Q2 FY27: revenue up 1.1% to $71.6M, swings to profit — Net income $4.5M ($0.15/sh) vs prior-year loss of $4.7M — Direct segment revenue +8.0%, comps +9.2%, fifth straight quarter of sequential improvement — Gross margin 59.8% vs 50.1% — but $7.7M of that is tariff refunds; ex-refunds margin still up ~40bps — Inventory down 28.4% YoY, cash $34.2M (2x last year), zero debt — Indirect segment revenue -39.4% on marketplace strategy shift and less liquidation — Reiterates FY27 sales guide $255-270M, operating loss improvement of 50%+ Real inflection in Direct/comps and balance sheet cleanup, but headline margin beat is partly a one-time tariff refund, not pure operating leverage Not financial advice.

$NUR NuRAN Wireless launches $50M ATM offering via H.C. Wainwright — Company can sell common shares opportunistically at market prices, no fixed size or timing — 3.0% cash commission to Wainwright on gross proceeds — US-only, none sold on the CSE — Proceeds earmarked for building/commissioning telecom sites, deployment opex, and working capital — NuRAN runs Network-as-a-Service rural mobile infra across Africa, 5,000+ sites under contract Standing dilution overhang now live — size and pace entirely at management's discretion Not financial advice.

$SUGP SU Group Holdings signs SPA to acquire 100% of KM Safety Solution Company — Via subsidiary SU Group Investment, buying from seller Lead New Limited — Aggregate consideration HK$5.616M (~$721K USD), cash at completion — Completion conditioned on due diligence satisfaction + required consents/approvals — Deadline Oct 31, 2026 — deal terminates automatically if conditions aren't met by then — No guarantee acquisition closes Small tuck-in deal, still fully conditional — real completion risk given the hard Oct 31 deadline Not financial advice.

$BDRX Biodexa strikes warrant exercise deal for $2.3M gross proceeds — Existing investor exercises warrants on 2.2M ADSs at $1.05, cash in — In exchange, gets new warrants on up to 4.4M ADSs, same $1.05 strike, immediately exercisable, 5-yr term — Maxim Group ran the inducement — New warrants unregistered/private placement, company must still file resale registration Classic warrant inducement structure — small cash raise now, but doubles the overhang with fresh 5-year warrants at depressed strike Not financial advice.

$CTNT Cheetah Net Supply Chain agrees to acquire JoyPak Supply for $788K cash — All-cash deal for 100% of JoyPak, closing expected within 4 weeks pending diligence — JoyPak sells consumer, beauty, and personal care products — Pushes Cheetah beyond its core logistics/warehousing and industrial-equipment trading business — Follows their Super International Trading acquisition from May 2026 Small bolt-on deal, but keeps stacking unrelated product lines onto a logistics shell — diversification pace worth watching Not financial advice.

$AGMH AGM Group outlines commercialization plans for desktop DePIN node with HashBeaver — ASIC-based device does SHA-256 Bitcoin mining, no AI training/inference on-device — Moving from pilot production toward volume production, certifications, sales channels — Longer term eyeing recurring revenue: node management subscriptions, AI ops assistant, cloud AI service integration via HashBeaver — Company explicitly flags no revenue yet — pilot inventory and channel interest aren't recognized sales — Complements their Sept 3 all-flash AI server volume production news Heavy on "intends to evaluate" language throughout — early-stage roadmap, not a revenue event Not financial advice.

$SDST Stardust Power secures long-lead electrical infrastructure with OG&E for Muskogee lithium refinery — OG&E locking down long-lead-time electrical equipment for large-scale industrial power delivery — Refinery site: 66 acres in Muskogee, OK, targeting up to 50,000 MTPA of battery-grade lithium carbonate — Built in two 25,000 MTPA phases — Framed as prep milestone ahead of future EPC construction phase Incremental infra milestone, not a construction start — still pre-EPC on the actual refinery build Not financial advice.

$BIVI BioVie reports topline Phase 2 ADDRESS-LC data for bezisterim in Long COVID — Full ITT population (203 pts): no endpoint hit statistical significance, but 21/22 trended in favor of drug — Pre-specified high-symptom-burden subgroups (~78% of trial) did hit significance across fatigue, PEM, and cognitive measures — Safety clean: 41.6% TEAE rate on drug vs 55.9% placebo, zero SAEs on bezisterim — DoW-funded trial ($13.13M), company says results support moving to Phase 3 — Conference call 8:30am ET today Key caveat baked into their own forward-looking language: primary ITT missed significance, all the signal is in subgroup analysis — that's hypothesis-generating, not confirmatory Not financial advice.

$PFSA Profusa regains Nasdaq compliance on bid price and equity rules — Letter received Sept 9, confirms compliance with Rule 5550(a)(2) and 5550(b)(1) — Still under a 1-year Mandatory Panel Monitor — any future equity-rule slip skips straight to delist determination, no compliance plan option — Has separate option agreement to acquire G3 Vision Labs, would go public diagnostics combo if exercised Delisting risk cleared for now, but the monitor period keeps the leash short Not financial advice.

$TRMD TORM prices 9M share secondary offering by Oaktree-linked selling shareholder — OCM Njord Holdings (Oaktree affiliate) selling 9M Class A shares for ~$290.25M gross — 30-day option for underwriter to buy up to 1.35M more shares — Company selling zero shares, receives zero proceeds — pure secondary — Seller owned ~20% of Class A shares pre-deal — J.P. Morgan sole underwriter, closes Sept 16 Pure overhang clearing — no dilution to TORM itself, just an existing large holder trimming down Not financial advice.

$PDSB PDS Biotech closes $11.3M initial tranche of up to $22.3M PIPE, adds Patrick Soon-Shiong to board — Led by Nant Capital at $0.2825/unit, shares + half-warrant structure — Milestone closing adds another $11M (Nant $10M, AB Group $1M) once PDS0301 Phase 3 protocol goes to FDA — Proceeds earmarked for debt paydown + advancing PDS0301 (IL-12 immunocytokine) toward late-stage trials — NantWorks also gets 1-yr exclusive negotiating option on PDS0101 HPV vaccine license — Soon-Shiong (ImmunityBio, NantHealth, LA Times) and NantBio CFO James Banaag join board Heavy dilution at a sub-$0.30 price, but brings a serious oncology name and fresh capital behind PDS0301's mCRC data Not financial advice.

$SYNX Silynxcom H1 2026: revenue up 174% YoY to $6.2M — Gross profit up 338% to $3.6M — Operating loss narrowed to $0.7M (from $1.6M in H1-25) — Asia revenue exploded to $3.1M vs just $0.1M a year ago — Cash on hand $2.6M, equity base $5M, receivables up 46% since Dec 2025 Tactical comms headset maker riding strong Asia demand, losses shrinking fast Not financial advice.

$MTNB GH Power signs first commercial hydrogen offtake deal with Change Energy/Hone for its Hamilton facility — Up to 1,000 kg/day of hydrogen supplied, intermittent availability during initial ramp — Deal runs 2 years from commercial ops start at Hamilton — Hamilton uses GH Power's aluminum-water reactor tech — no combustion, no carbon emissions, co-produces hydrogen + high-purity alumina — GH Power still pending its business combination with Matinas BioPharma (ticker MTNB currently reflects Matinas) First contracted revenue stream validating the reactor platform, though still tied to the pending SPAC-style merger closing Not financial advice.

$BWIN The Baldwin Group going private in $7.7B deal with Sequence Holdings and Michael Dell's family office — Shareholders get $32.50/share cash, 88% premium to unaffected price (June 17, 2026) — ~$4.6B equity value + ~$3.1B net debt assumed, ~20x trailing EBITDA — Colleagues roll over equity stake, no financing condition attached — Board and independent special committee both approved unanimously — Expected to close Q1 2027, delisting from Nasdaq after Insurance distribution platform going private with Dell family capital plus Sequence's tech buildout Not financial advice.

$EOSE Eos Energy gets $87M advance under DOE loan for Thorn Hill Line 2 — Reimburses 80% of eligible Line 2 build costs — Total drawn on DOE facility now ~$178M since 2024 — Line 2 hit commercial production June 2026, ramping toward ~2 GWh annual capacity — Once Line 1 relocates to Thorn Hill (pending lender approval), site targets ~4 GWh combined — Plans to staff Line 2 across 4 shifts Zinc-based LDES maker keeps drawing down DOE capital as domestic battery manufacturing scales Not financial advice.